High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
Top Cited Papers
- 12 January 2010
- journal article
- review article
- Published by Springer Nature in Immunologic Research
- Vol. 47 (1-3), 65-77
- https://doi.org/10.1007/s12026-009-8139-0
Abstract
Graft-versus-host disease, or GVHD, is a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) for the treatment of hematologic malignancies. Here, we describe a novel method for preventing GVHD after alloHSCT using high-dose, post-transplantation cyclophosphamide (Cy). Post-transplantation Cy promotes tolerance in alloreactive host and donor T cells, leading to suppression of both graft rejection and GVHD after alloHSCT. High-dose, post-transplantation Cy facilitates partially HLA-mismatched HSCT without severe GVHD and is effective as sole prophylaxis of GVHD after HLA-matched alloHSCT. By reducing the morbidity and mortality of alloHSCT, post-transplantation Cy may expand the applications of this therapy to the treatment of autoimmune diseases and non-malignant hematologic disorders such as sickle cell disease.Keywords
This publication has 64 references indexed in Scilit:
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on OutcomeTransplantation and Cellular Therapy, 2009
- Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2009
- Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2008
- Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseasesBone Marrow Transplantation, 2008
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T CellsTransplantation and Cellular Therapy, 2008
- Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host diseaseBlood, 2008
- Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved SurvivalTransplantation and Cellular Therapy, 2007
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980